148 related articles for article (PubMed ID: 18397649)
1. [Tyrosine kinase inhibitors in the treatment of polycythemia vera and related conditions. Danish Society of Hematology].
Larsen TS; Hasselbalch HC;
Ugeskr Laeger; 2008 Mar; 170(12):1031. PubMed ID: 18397649
[No Abstract] [Full Text] [Related]
2. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
Garber K
J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
[No Abstract] [Full Text] [Related]
3. JAK2 kinase inhibitors and myeloproliferative disorders.
Chen AT; Prchal JT
Curr Opin Hematol; 2010 Mar; 17(2):110-6. PubMed ID: 20087176
[TBL] [Abstract][Full Text] [Related]
4. An update of molecular pathogenesis and diagnosis of myeloproliferative disorders in the JAK2 era.
Zhang SJ; Li JY
Chin Med J (Engl); 2008 Sep; 121(18):1838-42. PubMed ID: 19080367
[No Abstract] [Full Text] [Related]
5. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
6. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
7. Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.
Panani AD
Cancer Lett; 2009 Oct; 284(1):7-14. PubMed ID: 19269737
[TBL] [Abstract][Full Text] [Related]
8. JAK2 mutations in polycythemia vera--molecular mechanisms and clinical applications.
Tefferi A
N Engl J Med; 2007 Feb; 356(5):444-5. PubMed ID: 17267904
[No Abstract] [Full Text] [Related]
9. Low frequency of JAK2 exon 12 mutations in classic and atypical CMPDs.
Ormazábal C; Hurtado C; Aranaz P; Erquiaga I; García-Delgado M; Calasanz MJ; Novo FJ; Vizmanos JL
Leuk Res; 2008 Sep; 32(9):1485-7. PubMed ID: 18291525
[No Abstract] [Full Text] [Related]
10. Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera.
Stuckey R; Gómez-Casares MT
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34068690
[TBL] [Abstract][Full Text] [Related]
11. An inhibitor of Janus kinase 2 prevents polycythemia in mice.
Mathur A; Mo JR; Kraus M; O'Hare E; Sinclair P; Young J; Zhao S; Wang Y; Kopinja J; Qu X; Reilly J; Walker D; Xu L; Aleksandrowicz D; Marshall G; Scott ML; Kohl NE; Bachman E
Biochem Pharmacol; 2009 Aug; 78(4):382-9. PubMed ID: 19413997
[TBL] [Abstract][Full Text] [Related]
12. [Targeted therapy of polycytemia vera patients].
Shikhbabaeva DI; Shuvaev VA; Martynkevich IS; Zyuzgin IS; Abdulkadyrov KM
Vopr Onkol; 2016; 62(4):386-93. PubMed ID: 30474944
[TBL] [Abstract][Full Text] [Related]
13. JAK2 inhibitors in polycythemia vera.
Quintás-Cardama A
Clin Adv Hematol Oncol; 2011 May; 9(5):397-400. PubMed ID: 21685869
[No Abstract] [Full Text] [Related]
14. Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms.
Stein BL; Crispino JD; Moliterno AR
Curr Opin Oncol; 2011 Nov; 23(6):609-16. PubMed ID: 21993415
[TBL] [Abstract][Full Text] [Related]
15. A unifying mutation in chronic myeloproliferative disorders.
Goldman JM
N Engl J Med; 2005 Apr; 352(17):1744-6. PubMed ID: 15858182
[No Abstract] [Full Text] [Related]
16. [Clinical aspects of myeloproliferative disorders excluding CML].
Komatsu N
Rinsho Ketsueki; 2008 Oct; 49(10):1411-9. PubMed ID: 18833926
[No Abstract] [Full Text] [Related]
17. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
Tefferi A
Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051
[TBL] [Abstract][Full Text] [Related]
18. Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms.
Eliaçık E; Işık A; Aksu S; Üner A; Büyükaşık Y; Sayınalp N; Göker H; Özcebe OI; Haznedaroğlu İC
Turk J Haematol; 2015 Jun; 32(2):163-7. PubMed ID: 26316485
[TBL] [Abstract][Full Text] [Related]
19. [JAK2 inhibitors in the treatment of myeloproliferative neoplasms].
Shide K
Rinsho Ketsueki; 2012 Oct; 53(10):1600-7. PubMed ID: 23037732
[No Abstract] [Full Text] [Related]
20. Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.
Walz C; Cross NC; Van Etten RA; Reiter A
Leukemia; 2008 Jul; 22(7):1320-34. PubMed ID: 18528425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
